Plasma levels of soluble glycoprotein 130 in acute myocardial infarction.
Soluble glycoprotein 130 (sgp130), a circulating form of receptor subunit for the interleukin (IL) -6 cytokine family, modulates the biological actions of its ligands as an inhibitory regulator. The role of sgpl30 in cardiovascular diseases such as acute coronary syndrome remains unknown. Plasma levels of sgp130 were examined by enzyme-linked immunosorbent assay in 33 patients with acute myocardial infarction (AMI; mean age 67 +/- 2 years, 21 males and 12 females), who were admitted to our hospital within 24 hr of onset of AMI and survived for 4 weeks. Plasma sgp130 levels were significantly higher at admission (260.5 +/- 7.3 ng/ml), and were significantly lower from day 2 to day 5 (202.4 +/- 5.1 ng/ml at day 3) as compared with normal control subjects (n = 38, 227.1 +/- 5.6 ng/ml). The lowest sgp130 levels inversely correlated with white blood cell count at admission (r = -0.42, p < 0.05) and with peak C-reactive protein levels (r = -0.43, p < 0.05). Additional in vitro study revealed that incubation of AMI plasma with exogenous IL-6 plus soluble IL-6 receptor resulted in a decrease in plasma sgp130 levels, suggesting the possible reason for reduced plasma sgp130 levels in AMI. The present study indicates that plasma sgp130 levels were modulated during the time course of AMI and inversely associated with inflammation in AMI.